Sensitivity to vandetanib in the MPM cell lines also fell within the range of IC50 values previously reported for other carcinoma cell lines, including pancreas, breast, colon, gastric and ovarian cancer cells with functional EGFR but lacking VEGFR-2 (Ciardiello et al, 2003; Bianco et al, 2006). This evidence concerns the gene EGFR and ovarian cancer.